2009Modern Rheumatology JournalOpen access

ETORICOXIB IS A NEW SELECTIVE CYCLOOXYGENASE-2 INHIBITOR

Andrey E. Karateev

Open full text 0 citations

Abstract

The paper provides the clinical characteristics of etoricoxib (Arcoxia), a new selective cyclooxygenase-2 inhibitor having unique properties, which permits it to be distinguished among other nonsteroidal anti-inflammatory agents.

Open-access reader

About this research paper

What this paper is about

The paper provides the clinical characteristics of etoricoxib (Arcoxia), a new selective cyclooxygenase-2 inhibitor having unique properties, which permits it to be distinguished among other nonsteroidal anti-inflammatory agents.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

The paper provides the clinical characteristics of etoricoxib (Arcoxia), a new selective cyclooxygenase-2 inhibitor having unique properties, which permits it to be distinguished among other nonsteroidal anti-inflammatory agents.

Key concepts: Etoricoxib, Cyclooxygenase, Nonsteroidal, Pharmacology, Chemistry, Medicine, Biochemistry, Enzyme

Related papers

Back to paper searchBrowse research topicsOriginal source
ETORICOXIB IS A NEW SELECTIVE CYCLOOXYGENASE-2 INHIBITOR — Research Paper | ScholarLens